The GLP-1 effect: Innovative care delivery models and compliant disease management

By James Ravitz, Jayda Greco, Paul Gadiock and Jae Hyun Lee on October 14, 2025

Posted In Employee Benefits, Health and Welfare Plans

GLP-1 therapies are transforming obesity and chronic disease treatment, yet navigating their complex regulatory landscape remains critical. From the Food and Drug Administration’s ‘Green List’ to state-specific rules, compliance isn’t optional – it’s a strategic advantage.

In a recent webinar, McDermott Will & Schulte’s Health & Life Sciences Group explored strategies for scaling GLP-1 programs, covering topics like innovative care delivery models, direct-to-consumer advertising enforcement, and compliance best practices.

Access the webinar recording and key takeaways here.

Tags: direct-to-consumer advertising enforcement, FDA, Food and Drug Administration, GLP-1, Green List

James Ravitz
James (Jamie) Ravitz is the co-head of the Firm’s Life Sciences industry practice and head of McDermott’s Food and Drug Administration (FDA) practice. He works alongside clients across the entire spectrum of life sciences and healthcare law, including regulatory counsel, compliance, and investigations and government enforcement. He is particularly focused on Food and Drug Administration (FDA) regulatory counseling. Jamie works in partnership with companies and investors across the complete ecosystem of FDA-regulated products—drugs, devices, health technologies, biologics, food, cosmetics and cannabis— to help them achieve their business goals. Read James R. Ravitz's full bio.

Jayda Greco
Jayda Greco works at the intersection of healthcare regulatory, privacy and compliance, product counseling and marketing law, with particular emphasis on digital health products and services. Often working cross-functionally with stakeholders in sales, finance, marketing and product, Jayda is adept at devising creative and practical legal solutions for digital health initiatives to meet business objectives. Read Jayda Greco's full bio.

Paul Gadiock
Paul Gadiock leverages his firsthand experience at the Food and Drug Administration (FDA) to provide life sciences, healthcare and other FDA-regulated companies with practical, strategic counsel at every phase of the product life cycle. Paul supports medical device, digital therapeutic, and biopharma companies, software as a medical device (SaMD) and clinical decision support (CDS) developers, and their investors on their FDA regulatory and due diligence needs, delivering premarket and postmarket regulatory guidance to maximize business outcomes. Read Paul S. Gadiock's full bio.

Jae Hyun Lee
Jae Hyun Lee is a member of the Healthcare Practice Group. He focuses his practice on healthcare mergers and acquisitions as well as regulatory and compliance matters.Read Jae Hyun Lee's full bio.

The GLP-1 effect: Innovative care delivery models and compliant disease management

Related Posts

BLOG EDITORS

STAY CONNECTED

TOPICS

ARCHIVES

RECENT POSTS